Fibrinolysis is impaired in patients with primary immune thrombocytopenia

J Thromb Haemost. 2024 Nov;22(11):3209-3220. doi: 10.1016/j.jtha.2024.07.034. Epub 2024 Aug 28.

Abstract

Background: Patients with primary immune thrombocytopenia (ITP) have an increased risk of thrombosis, which may be due to altered fibrinolysis.

Objectives: To elucidate the clinical impact of delayed fibrinolysis in ITP patients.

Methods: A turbidimetric clot formation and lysis assay and a fluorometric plasmin generation (PG) assay were performed, and levels of plasminogen activator inhibitor-1 (PAI-1), tissue plasminogen activator (tPA), tPA-PAI-1 complexes, α2-antiplasmin, thrombin activatable fibrinolysis inhibitor, and D-dimer were assessed in 86 adult primary ITP patients and 78 healthy controls (HCs).

Results: ITP patients showed significantly delayed clot formation, increased clot density, and prolonged clot lysis time (CLT) compared with HCs, with a median (IQR) CLT of 28.0 (13.7-34.7) minutes in patients and 17.3 (12.0-28.0) minutes in HCs, while in the PG assay, only the lag time was prolonged. In ITP patients compared with controls, PAI-1 was higher (1.2 [0.8-2.6] vs 1.1 [0.6-2.1] U/mL) and tPA antigen and activity were lower (tPA antigen: 2.6 [1.1-4.4] vs 3.7 [3.2-4.7] ng/mL; tPA activity ≤ 0 U/mL: 26% vs 7%). TPA-PAI-1 complex levels were positively associated with CLT in multiple linear regression analysis (β = 0.241; P = .019), whereas PG parameters were not associated with CLT. Six patients who developed thrombosis during follow-up had higher levels of tPA-PAI-1 complexes.

Conclusion: Prolonged CLT and delayed onset of PG may indicate a hypofibrinolytic tendency in ITP patients, as also indicated by high PAI-1 and low tPA levels. No association was found between fibrinolytic potential and the bleeding phenotype, whereas higher tPA-PAI-1 complex levels were associated with prolonged CLT and increased in patients with future thrombosis.

Keywords: blood coagulation tests; clot lysis time; fibrinolysis; immune thrombocytopenia; plasmin generation.

MeSH terms

  • Adult
  • Aged
  • Biomarkers / blood
  • Carboxypeptidase B2 / blood
  • Case-Control Studies
  • Female
  • Fibrin Clot Lysis Time
  • Fibrin Fibrinogen Degradation Products / analysis
  • Fibrin Fibrinogen Degradation Products / metabolism
  • Fibrinolysin / analysis
  • Fibrinolysin / metabolism
  • Fibrinolysis*
  • Humans
  • Male
  • Middle Aged
  • Plasminogen Activator Inhibitor 1* / blood
  • Purpura, Thrombocytopenic, Idiopathic* / blood
  • Purpura, Thrombocytopenic, Idiopathic* / diagnosis
  • Thrombosis* / blood
  • Thrombosis* / diagnosis
  • Time Factors
  • Tissue Plasminogen Activator* / blood
  • alpha-2-Antiplasmin / analysis
  • alpha-2-Antiplasmin / metabolism

Substances

  • Plasminogen Activator Inhibitor 1
  • Tissue Plasminogen Activator
  • SERPINE1 protein, human
  • Fibrin Fibrinogen Degradation Products
  • alpha-2-Antiplasmin
  • fibrin fragment D
  • Fibrinolysin
  • Carboxypeptidase B2
  • Biomarkers
  • PLAT protein, human
  • CPB2 protein, human